Literature DB >> 10815773

Conformational analysis of a farnesyltransferase peptide inhibitor, CVIM.

L Carlacci1.   

Abstract

The conformational states of the peptide Cys-Val-Ile-Met (or CVIM) were computed and characterized. CVIM inhibits farnesylation of the Ras oncogene product, p21ras, at the cysteine residue of the C-terminal segment. CVIM is active in an extended conformation. A similar peptide (KTKCVFM) appears to bind the enzyme in the Type I bend conformation. In the present study, the conformations of CVIM were computed in an aqueous environment with the peptide in the zwitterionic state. Solvation free energy based on solvent accessible surface area and a distance dependent dielectric were used in the calculations. Final conformations of multiple independent Monte Carlo simulated annealing (MCSA) conformational searches were used as starting points for Metropolis Monte Carlo (MMC) runs. Conformations saved at intervals during MMC runs were analyzed. Conformers were separated by interactive clustering in dihedral angle coordinates. The four lowest energy conformers corresponding to a Type I bend, extended, AB-bend, and BA-bend were within 0.3 kcal/mol of each other, and dominant in terms of population. The Type I bend and extended conformers were supported by the binding studies. The extended conformer was the most populated. In the AB-bend conformer, 'A' indicates the alpha-helix conformation of Val, and 'B' indicates the beta-strand conformation of Ile. The AB- and BA-bend conformations differed from the extended conformation in the value of Val psi and Ile psi, respectively, and from the Type I bend conformation in the value of Ile psi and Val psi, respectively. The four lowest energy conformers were characterized in terms of energy, density of low energy conformations (or entropy), structure, side chain rotamer fraction population, and interatomic distances.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815773     DOI: 10.1023/a:1008175919794

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  19 in total

1.  Empirical solvation models can be used to differentiate native from near-native conformations of bovine pancreatic trypsin inhibitor.

Authors:  J Vila; R L Williams; M Vásquez; H A Scheraga
Journal:  Proteins       Date:  1991

2.  Atomic solvation parameters applied to molecular dynamics of proteins in solution.

Authors:  L Wesson; D Eisenberg
Journal:  Protein Sci       Date:  1992-02       Impact factor: 6.725

Review 3.  The biochemistry of ras p21.

Authors:  R J Grand; D Owen
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

4.  On the entropy of protein folding.

Authors:  G I Makhatadze; P L Privalov
Journal:  Protein Sci       Date:  1996-03       Impact factor: 6.725

Review 5.  The anatomy and taxonomy of protein structure.

Authors:  J S Richardson
Journal:  Adv Protein Chem       Date:  1981

6.  All ras proteins are polyisoprenylated but only some are palmitoylated.

Authors:  J F Hancock; A I Magee; J E Childs; C J Marshall
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

7.  Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.

Authors:  Y Qian; M A Blaskovich; M Saleem; C M Seong; S P Wathen; A D Hamilton; S M Sebti
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

Review 8.  Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity.

Authors:  C J Der; A D Cox
Journal:  Cancer Cells       Date:  1991-09

9.  A CHARMM analysis of the conformations of the metastasis-inhibiting laminin pentapeptide.

Authors:  D R McKelvey; C L Brooks; M Mokotoff
Journal:  J Protein Chem       Date:  1991-06

10.  Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.

Authors:  Y Qian; A Vogt; S M Sebti; A D Hamilton
Journal:  J Med Chem       Date:  1996-01-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.